全文获取类型
收费全文 | 1633篇 |
免费 | 110篇 |
国内免费 | 64篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 58篇 |
妇产科学 | 4篇 |
基础医学 | 197篇 |
口腔科学 | 25篇 |
临床医学 | 121篇 |
内科学 | 489篇 |
皮肤病学 | 28篇 |
神经病学 | 140篇 |
特种医学 | 260篇 |
外科学 | 68篇 |
综合类 | 91篇 |
预防医学 | 113篇 |
眼科学 | 5篇 |
药学 | 165篇 |
肿瘤学 | 40篇 |
出版年
2023年 | 2篇 |
2022年 | 6篇 |
2021年 | 25篇 |
2020年 | 12篇 |
2019年 | 6篇 |
2018年 | 17篇 |
2017年 | 14篇 |
2016年 | 29篇 |
2015年 | 34篇 |
2014年 | 41篇 |
2013年 | 37篇 |
2012年 | 45篇 |
2011年 | 76篇 |
2010年 | 53篇 |
2009年 | 50篇 |
2008年 | 75篇 |
2007年 | 90篇 |
2006年 | 92篇 |
2005年 | 90篇 |
2004年 | 60篇 |
2003年 | 61篇 |
2002年 | 58篇 |
2001年 | 54篇 |
2000年 | 44篇 |
1999年 | 50篇 |
1998年 | 68篇 |
1997年 | 66篇 |
1996年 | 58篇 |
1995年 | 59篇 |
1994年 | 38篇 |
1993年 | 42篇 |
1992年 | 20篇 |
1991年 | 23篇 |
1990年 | 24篇 |
1989年 | 52篇 |
1988年 | 37篇 |
1987年 | 32篇 |
1986年 | 21篇 |
1985年 | 21篇 |
1984年 | 12篇 |
1983年 | 10篇 |
1982年 | 16篇 |
1981年 | 18篇 |
1980年 | 19篇 |
1979年 | 11篇 |
1978年 | 5篇 |
1977年 | 14篇 |
1976年 | 11篇 |
1975年 | 8篇 |
1966年 | 1篇 |
排序方式: 共有1807条查询结果,搜索用时 31 毫秒
51.
52.
53.
Coakley G; Mok CC; Hajeer AH; Ollier WE; Turner D; Sinnott PJ; Hutchinson IV; Panayi GS; Lanchbury JS 《Rheumatology (Oxford, England)》1998,37(9):988-991
OBJECTIVE: To examine whether promoter polymorphisms associated with
variation in interleukin-10 (IL-10) production are relevant to the
development of rheumatoid arthritis (RA) or Felty's syndrome (FS). METHODS:
DNA was obtained from 44 FS patients, 117 RA patients and 295 controls. The
promoter region between -533 and - 1120 was amplified by polymerase chain
reaction, and polymorphisms detected by restriction enzyme digest or
sequence-specific oligonucleotide probing. RESULTS: We found no significant
difference in allele or haplotype frequencies between the groups.
CONCLUSION: There is no association between FS or RA and these recently
identified IL-10 promoter polymorphisms. Other genetic or environmental
factors could explain the alterations in IL-10 levels seen in these
conditions.
相似文献
54.
Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group 总被引:26,自引:0,他引:26
R Rooke M Tremblay H Soudeyns L DeStephano X J Yao M Fanning J S Montaner M O'Shaughnessy K Gelmon C Tsoukas 《AIDS (London, England)》1989,3(7):411-415
We determined whether drug-resistant variants of HIV-1 could be isolated from the peripheral blood mononuclear cells of 20 individuals with HIV infection (Centers for Disease Control groups II and III) on long-term zidovudine (AZT) therapy. Toward this end, zidovudine (10 microM) has been included in the tissue culture medium used to isolate HIV-1. Under these circumstances, virus with a zidovudine-resistant phenotype was successfully obtained in five out of 20 cases. This property of drug resistance appeared to be stable, and did not disappear upon extended replication of such virus in the absence of drug pressure. Drug-resistant virus could also be isolated from these subjects on subsequent occasions, but was not present in samples obtained prior to therapy. Replication of these zidovudine-resistant isolates in tissue culture was inhibited by each of four other nucleoside analogues. Thus, other drugs may be useful in controlling selective zidovudine-resistant variants of HIV-1. 相似文献
55.
Castillo Laita JA De Benito Fernández J Escribano Montaner A Fernández Benítez M García de la Rubia S Garde Garde J García-Marcos L González Díaz C Ibero Iborra M Navarro Merino M Pardos Martínez C Pellegrini Belinchon J Sánchez Jiménez J Sanz Ortega J Villa Asensi JR 《Allergologia et immunopathologia》2008,36(1):31-52
56.
Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial 总被引:4,自引:0,他引:4
K Gelmon J S Montaner M Fanning J R Smith J Falutz C Tsoukas J Gill G Wells M O'Shaughnessy M Wainberg 《AIDS (London, England)》1989,3(9):555-561
To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study. Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease. Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals. Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day. Clinical and laboratory evaluations were performed at 3-week intervals. Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%). These were generally self-limited, reappearing briefly at each dose increment. A decrease in hemoglobin occurred shortly after initiation of therapy. This was not dose dependent and reversed rapidly upon discontinuation of treatment. A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase. The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day. Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
57.
Journal of Neuroimmune Pharmacology - The original version of this article unfortunately contained mistakes. 相似文献
58.
Marco Gerlinger Sergio A Quezada Karl S Peggs Andrew JS Furness Rosalie Fisher Teresa Marafioti Vishvesh H Shende Nicholas McGranahan Andrew J Rowan Steven Hazell David Hamm Harlan S Robins Lisa Pickering Martin Gore David L Nicol James Larkin Charles Swanton 《The Journal of pathology》2013,231(4):424-432
The recognition of cancer cells by T cells can impact upon prognosis and be exploited for immunotherapeutic approaches. This recognition depends on the specific interaction between antigens displayed on the surface of cancer cells and the T cell receptor (TCR), which is generated by somatic rearrangements of TCR α‐ and β‐chains (TCRb). Our aim was to assess whether ultra‐deep sequencing of the rearranged TCRb in DNA extracted from unfractionated clear cell renal cell carcinoma (ccRCC) samples can provide insights into the clonality and heterogeneity of intratumoural T cells in ccRCCs, a tumour type that can display extensive genetic intratumour heterogeneity (ITH). For this purpose, DNA was extracted from two to four tumour regions from each of four primary ccRCCs and was analysed by ultra‐deep TCR sequencing. In parallel, tumour infiltration by CD4, CD8 and Foxp3 regulatory T cells was evaluated by immunohistochemistry and correlated with TCR‐sequencing data. A polyclonal T cell repertoire with 367–16 289 (median 2394) unique TCRb sequences was identified per tumour region. The frequencies of the 100 most abundant T cell clones/tumour were poorly correlated between most regions (Pearson correlation coefficient, –0.218 to 0.465). 3–93% of these T cell clones were not detectable across all regions. Thus, the clonal composition of T cell populations can be heterogeneous across different regions of the same ccRCC. T cell ITH was higher in tumours pretreated with an mTOR inhibitor, which could suggest that therapy can influence adaptive tumour immunity. These data show that ultra‐deep TCR‐sequencing technology can be applied directly to DNA extracted from unfractionated tumour samples, allowing novel insights into the clonality of T cell populations in cancers. These were polyclonal and displayed ITH in ccRCC. TCRb sequencing may shed light on mechanisms of cancer immunity and the efficacy of immunotherapy approaches. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. 相似文献
59.
60.
Montaner AD Mongiat L Lux-Lantos VA Warby C Chewpoy B Bianchi MS Libertun C Rivier JE Sherwood NM Somoza GM 《Neuroendocrinology》2002,75(5):326-338
Gonadotropin-releasing hormone (GnRH) is a decapeptide widely known for its role in regulating vertebrate reproduction by serving as a signal from the hypothalamus to pituitary gonadotropes. The first form of GnRH to be identified was isolated from mammals (mGnRH) and the same form has been reported for all mammals studied, which includes marsupials and placental mammals. Later, another variant, chicken GnRH-II (cGnRH-II) was shown to be expressed together with mGnRH in the brains of all jawed vertebrates, including mammals such as rats, monkeys and humans. Our objective was to characterize a third form of GnRH that was isolated previously as mRNA from guinea pigs (gpGnRH), but has not been reported for any other mammal to date. Furthermore, the gonadotropic activity of gpGnRH has not been fully characterized. Our results, using chromatographical and immunological methods, show for the first time that gpGnRH is expressed together with mGnRH in some rodents (wild guinea pig and capybara), but not in others (mouse and hamster). Also, the gonadotropic activity of gpGnRH and mGnRH was tested in two different rat cell culture systems. Although there have been reports that the salmon(s) form of GnRH is present in mammals, we did not detect sGnRH in capybara, wild guinea pigs, hamsters, rats or mice. Taken together with previous reports, the present results support the idea that the expression of multiple GnRH variants in a single species is a common pattern in most vertebrate groups. 相似文献